Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Regulatory Shakeup: Top Regulator Out, Commissioner Reprimanded Amid Vaccine Scandal

Executive Summary

Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.

You may also be interested in...



Nine Catalysts For China Biopharma In 2019

After much turmoil in 2018, the biopharma sector in China is embracing multiple uncertainties in the year of the boar.

Eight For 8: Things You Need To Know About China Biopharma Regulation In 2018

The Pink Sheet's pick of eight major events that captured major regulatory developments in China’s dynamic, highly fluid biopharma scene in 2018.

Bye Bye CFDA, Hello NMPA: China Regulatory Express

In the latest in a series of regulatory changes in China, the national drugs regulator has apparently been renamed the National Medical Products Administration (NMPA), while the country's essential drugs list has been expanded to include more oncology and pediatric drugs, which will be fully reimbursed.

Related Content

Topics

UsernamePublicRestriction

Register

PS123709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel